Pharmacokinetic study validates a rapid LC-MS/MS assay for pemafibrate in rat plasma, suggesting improved detection for low-dose therapeutic evaluations.
Background: Pemafibrate, a novel selective peroxisome proliferator-activated receptor-α modulator, is prescribed for patients with dyslipidemia. To investigate other potential nonlipid-related effects of pemafibrate, the sensitive and rapid quantitation method for pemafibrate was required. Results: The developed LC–MS/MS assay method exhibited excellent accuracy, precision, sensitivity, stability, no matrix effect and high recovery. The LOQ (0.05 ng/ml) and run time (6.0 min) were superior to previous reports. The calibration curve showed good linearity over the wide concentration range (0.05–100.00 ng/ml). This validated method was successfully applied in a rat pharmacokinetic study using lower doses (0.02 or 0.10 mg/kg) than have been previously reported. Conclusion: This method can support gathering data for the evaluation of pemafibrate in future studies.
No takes yet. Share an insight, caveat, or question.
Kobuchi et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: